根据名称进行药物检索

Fluconazole Injection Solution 与 Glynase PresTab

Fluconazole Injection Solution 与 Glynase PresTab互相作用以及同时服用的可能性。

检测结果:

Fluconazole Injection Solution <> Glynase PresTab

现实性: 06.07.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

氟康唑可能增加的血液水平和效果的优降糖. 你可能会更有可能遇到的低血糖、低血糖、在处理与这些药物。低血糖症状包括头痛、头晕、睡意、紧张、混乱、震颤、恶心、饥饿、弱点、出汗，心悸，而快速的心跳。严重的低血糖了，偶尔报道，这可能导致昏迷甚至死亡，尤其是在老年人和患有肾脏和/或肝脏问题。监视你的血糖水平密切合作。你可能需要调整剂量的优降糖期间和之后处理与氟康唑。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

密切监测:共同给予的抑制剂CYP450 2C9包括某些类抗真菌剂，例如氟康唑，咪康唑和种药物可能增加等离子浓度磺酰脲，其中许多已被发现是基于同工酶. 药物动力学数据提供单剂量管理的氯磺丙脲(250毫克)，甲糖宁(500毫克)，嗪(2.5毫克)，优降糖(5毫克)，和美脲(0.5毫克)结合氟康唑。在健康研究的主题，氟康唑100毫克每天7天增加了单剂量的系统性风险(AUCs)的各种磺酰脲通过一个平均值的几乎30%(氯磺丙脲,甲糖宁)几乎50%(嗪、优降糖). 意思是血糖水平的变化不是统计上的显着在这些研究中，虽然大约48%的患者处理的氟康唑经历的症状符合低血糖相比，40%患者的治疗与安慰剂。四分之一的氟康唑治疗的患者在优降糖研究还需要口头葡萄糖。较高剂量的氟康唑(400毫克一天，随后通过200毫克每天为3天)增加了单剂量美脲哥伦比亚联合自卫军的138%和延长其半衰期从2.0至3.3小时健康的志愿者。在另一项研究，低剂量的氟康唑(50毫克/天)给予治外阴阴道的念珠菌病在14绝经后的糖尿病的妇女收到格列齐特或优降糖疗证明不影响血液中的葡萄糖的控制；药物动力学的数据都不包括在内。根据现有数据使用氟康唑不会出现是相关的重大风险的严重的低血糖在剂量 <200毫克>
管理：谨慎建议时磺酰脲用伴随唑抗真菌剂抑制CYP450 2C9. 血液中的葡萄糖应密切监测，并磺酰剂量调整是必要的。病人也应该获悉的风险增加的低血糖和警觉到潜在的迹象和症状，例如头疼、头晕、睡意、紧张、混乱、震颤、饥饿、弱点、出汗，心悸，而性心动过速。如果是低血糖的出现，患者应开始适当的补救治疗，立即停止唑真菌剂和接触他们的医生。

来源

Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7
"Product Information. Monistat (miconazole)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG "Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas." Pharmacogenomics 10 (2009): 1781-7
Jeong S, Nguyen PD, Desta Z "Comprehensive in vitro inhibition analysis of eight cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A." Antimicrob Agents Chemother 53 (2009): 541-51
"Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.
"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.
Miners JO, Birkett DJ "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism." Br J Clin Pharmacol 45 (1998): 525-38
Rowe BR, Thorpe J, Barnett A "Safety of fluconazole in women taking oral hypoglycaemic agents." Lancet 339 (1992): 255-6
Pond SM, Birkett DJ, Wade DN "Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole." Clin Pharmacol Ther 22 (1977): 573-9
Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200
Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S "Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide." Clin Pharmacol Ther 88 (2010): 214-22
Venkatakrishnan K, von Moltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance." Clin Pharmacokinet 38 (2000): 111-80
"Product Information. Diflucan (fluconazole)." Roerig Division, New York, NY.
Tirkkonen T, Heikkila P, Huupponen R, Laine K "Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide." J Intern Med 268 (2010): 359-66
Shon JH, Yoon YR, Kim MJ, et al. "Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism." Br J Clin Pharmacol 59 (2005): 552-63
Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT "Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes." Clin Pharmacol Ther 72 (2002): 326-32
Shobha JC, Muppidi MR "Interaction between voriconazole and glimepiride." J Postgrad Med 56 (2010): 44-5
Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33
"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.
Niwa T, Shiraga T, Takagi A "Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes." Biol Pharm Bull 28 (2005): 1805-8
Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y "Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments." Drug Metab Disposition 28 (2000): 475-81
Holstein A, Plaschke A, Ptak M, et al. "Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents." Br J Clin Pharmacol 60 (2005): 103-6
"Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.
Back DJ, Tjia JF, Karbwang J, Colbert J "In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones." Br J Clin Pharmacol 26 (1988): 23-9
"Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.